Chronic inflammation is a key pathological hallmark of multiple sclerosis and suggests that resolution of inflammation, orchestrated by specialized pro-resolving lipid mediators, is impaired. Here, through targeted-metabololipidomics in peripheral blood of patients with multiple sclerosis, we revealed that each disease form was associated with distinct lipid mediator profiles that significantly correlated with disease severity. In particular, relapsing and progressive multiple sclerosis patients were associated with high eicosanoids levels, whereas the majority of pro-resolving lipid mediators were significantly reduced or below limits of detection and correlated with disease progression. Furthermore, we found impaired expression of several pro-resolving lipid mediators biosynthetic enzymes and receptors in blood-derived leukocytes of MS patients. Mechanistically, differentially expressed mediators like LXA4, LXB4, RvD1 and PD1 reduced multiple sclerosis-derived monocyte activation and cytokine production and inhibited inflammation-induced blood-brain barrier dysfunction and monocyte transendothelial migration. Altogether, these findings reveal peripheral defects in the resolution pathway in multiple sclerosis, suggesting pro-resolving lipid mediators as novel diagnostic biomarkers and potentially safe therapeutics.

Specialized pro-resolving lipid mediators are differentially altered in peripheral blood of patients with multiple sclerosis and attenuate monocyte and blood-brain barrier dysfunction / Kooij, Gijs; Derada Troletti, Claudio; Leuti, Alessandro; Norris, Paul C; Riley, Ian; Albanese, Maria; Ruggieri, Serena; Libreros, Stephania; van der Pol, Susanne M A; van Het Hof, Bert; Schell, Yoëlle; Guerrera, Gisella; Buttari, Fabio; Mercuri, Nicola Biagio; Centonze, Diego; Gasperini, Claudio; Battistini, Luca; de Vries, Helga E; Serhan, Charles N; Chiurchiù, Valerio. - In: HAEMATOLOGICA. - ISSN 0390-6078. - 105:8(2019), pp. 2056-2070. [10.3324/haematol.2019.219519]

Specialized pro-resolving lipid mediators are differentially altered in peripheral blood of patients with multiple sclerosis and attenuate monocyte and blood-brain barrier dysfunction

Ruggieri, Serena;Gasperini, Claudio;
2019

Abstract

Chronic inflammation is a key pathological hallmark of multiple sclerosis and suggests that resolution of inflammation, orchestrated by specialized pro-resolving lipid mediators, is impaired. Here, through targeted-metabololipidomics in peripheral blood of patients with multiple sclerosis, we revealed that each disease form was associated with distinct lipid mediator profiles that significantly correlated with disease severity. In particular, relapsing and progressive multiple sclerosis patients were associated with high eicosanoids levels, whereas the majority of pro-resolving lipid mediators were significantly reduced or below limits of detection and correlated with disease progression. Furthermore, we found impaired expression of several pro-resolving lipid mediators biosynthetic enzymes and receptors in blood-derived leukocytes of MS patients. Mechanistically, differentially expressed mediators like LXA4, LXB4, RvD1 and PD1 reduced multiple sclerosis-derived monocyte activation and cytokine production and inhibited inflammation-induced blood-brain barrier dysfunction and monocyte transendothelial migration. Altogether, these findings reveal peripheral defects in the resolution pathway in multiple sclerosis, suggesting pro-resolving lipid mediators as novel diagnostic biomarkers and potentially safe therapeutics.
2019
Cell Therapy and Immunotherapy; Granulocytes, Monocytes, Macrophages; Immunophenotyping; lipid; multiple sclerosis
01 Pubblicazione su rivista::01a Articolo in rivista
Specialized pro-resolving lipid mediators are differentially altered in peripheral blood of patients with multiple sclerosis and attenuate monocyte and blood-brain barrier dysfunction / Kooij, Gijs; Derada Troletti, Claudio; Leuti, Alessandro; Norris, Paul C; Riley, Ian; Albanese, Maria; Ruggieri, Serena; Libreros, Stephania; van der Pol, Susanne M A; van Het Hof, Bert; Schell, Yoëlle; Guerrera, Gisella; Buttari, Fabio; Mercuri, Nicola Biagio; Centonze, Diego; Gasperini, Claudio; Battistini, Luca; de Vries, Helga E; Serhan, Charles N; Chiurchiù, Valerio. - In: HAEMATOLOGICA. - ISSN 0390-6078. - 105:8(2019), pp. 2056-2070. [10.3324/haematol.2019.219519]
File allegati a questo prodotto
File Dimensione Formato  
1052056.pdf

accesso aperto

Tipologia: Documento in Post-print (versione successiva alla peer review e accettata per la pubblicazione)
Licenza: Creative commons
Dimensione 2.24 MB
Formato Adobe PDF
2.24 MB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1408812
Citazioni
  • ???jsp.display-item.citation.pmc??? 37
  • Scopus 60
  • ???jsp.display-item.citation.isi??? 62
social impact